MedTrace Logo

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

NCT00116610 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2009-01-21

No results posted yet for this study

Summary

This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

Conditions

Interventions

DRUG

picoplatin

Sponsors & Collaborators

  • Poniard Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Hazel Breitz, MD · Poniard Pharmaceuticals

  • Paul Weiden, MD · Poniard Pharmaceuticals

  • David Karlin, MD · Poniard Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-03-31
Completion
2008-03-31

Countries

  • United States
  • Canada
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116610 on ClinicalTrials.gov